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Patricia Ibanez Toro,5 Maria Vadalà,6 Salvatore Cillino ,7 Gianni Virgili,8 Rosa Gini,9
Olivia Leoni,10 Sebastiano Walter Pollina Addario,11 Pasquale Cananzi,12
Claudia La Cavera,12 Maria Rosalia Puzo,5 Giovambattista De Sarro,13
Adele De Francesco,14 and Gianluca Trifirò 1,2
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Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims
databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product
characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were
validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received
≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy)
per 10,000 persons while intravitreal dexamethasone use ranged from 0.2 (Basilicata) to 1.4 (Lombardy) per 10,000 persons.
Overall, 40,815 persons were incident users of study drugs. Among incident users with ≥1 year of follow-up (N� 30,745), 16.0%
(N� 4,890) had only one pharmacy claim, especially for ranibizumab (60.9%). Switching occurred in 8.0% of users with ≥2
pharmacy claims (N� 33,637). )e algorithms had an accuracy of 83.8 (95% CI: 79.7–87.3) concerning bilateral treatment and
72.3% (95% CI: 67.5–76.8) for DME. Conclusion. Study drug use increased over time in Lombardy, Basilicata, Calabria, and Sicily,
despite a large heterogeneity in prevalence of use across regions. Drug treatment appeared to be partly in line with SPC, suggesting
that improvement in clinical practice may be needed to maximize drug benefits.
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1. Introduction
)e most common neovascular diseases responsible for
visual impairment are age-related macular degeneration
(AMD), diabetic macular edema (DME), retinal vein oc-
clusion (RVO), and choroidal neovascularization secondary
to pathological myopia (mCNV) [1, 2]. Intravitreal anti-
vascular endothelial growth factor (anti-VEGF) drugs and
dexamethasone have significantly improved clinical out-
comes in these diseases [3]. )e intravitreal anti-VEGF
drugs pegaptanib, ranibizumab, and aflibercept are indicated
in AMD, DME, RVO, and mCNV [4–6], while intravitreal
bevacizumab is widely used off-label for AMD and DME [7].
Two glucocorticoid drugs, dexamethasone and fluocinolone
acetonide intravitreal implants, are also approved for DME
[8, 9].
)e National Institute of Health and Clinical Excellence
(NICE) guidance recommends first-line use of ranibizumab
and aflibercept in AMD and DME. According to the
summary of product characteristics (SPC), the induction
phase for aflibercept and ranibizumab for all retinal diseases
except mCNV is initially similar, with some slight differ-
ences: one monthly injection for three or five consecutive
months, respectively [5, 6]. After the induction phase, the
maintenance phase involves two different recommended
treatment regimens: the treat-and-extend approach involves
increasing or decreasing intervals between monthly injec-
tions by two weeks, while the pro re nata (PRN) approach
involves one injection as needed. Pegaptanib injections
should be administered once every six weeks [4]. Whatever
the treatment regimen used, the interval between two
consecutive injections in the same eye should be at least four
weeks [5, 6]. )e treatment regimen for the dexamethasone
implant is simpler than that for intravitreal anti-VEGF
drugs: one implant is inserted approximately every six
months for the treatment of either DME or RVO [8]. Further
information on all therapeutic particulars for anti-VEGF
drugs and dexamethasone is available in Supplementary
Material 1.
To date, it is not known how intravitreal drugs are
used in Italian clinical practice. )e primary objective of
this study was to describe the utilization pattern of these
drugs in Italy while the secondary objective was to
measure the diagnostic performance of algorithms to
identify bilaterally treated patients and DME in claims
databases.
2. Methods
2.1. Data Source. A retrospective, drug utilization study was
conducted using fully anonymized data from the claims
databases of Lombardy, Sicily, Calabria, and Basilicata re-
gions from 2010 to 2016 (Supplementary Material 2). )e
national demographic data published by the Italian Institute
of Statistics was used to calculate the crude yearly number of
inhabitants in each region, i.e., the underlying population in
the catchment areas [10].
)e four databases used were claims databases linked
through a unique patient identifier: a demographic registry,
containing demographic patient information, hospital dis-
charge diagnosis database, emergency department admis-
sions database, and diagnostic and laboratory tests ordered.
)e Anatomical )erapeutic Chemical (ATC) classification
system is used to code drug information on drugs. Diagnoses
are coded using the International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9 CM) [11].
To complement the claims data, clinical data was col-
lected prospectively in three large ophthalmological centres
in Sicily using a case report form (CRF). )e CRF contains a
range of clinical information related to the ophthalmologic
visit for each patient. Information was collected at the first
visit to the clinic and at each of the following visits, including
check-up visits or visits for drug administration. CRF data
was considered as the gold standard given that data col-
lection was carefully curated specifically for research
purposes.
2.2. Study Drugs. )e study drugs of interest were dexa-
methasone intravitreal implant (ATC: S01BA01), ranibizu-
mab (ATC: S01LA04), aflibercept (ATC: S01LA05), and
pegaptanib (ATC: S01LA03). Due to the difficulty of tracing
the off-label intravitreal use of bevacizumab using claims
databases, this drug was not included. As fluocinolone
acetonide was marketed in 2017, this could not be identified
using the data available.)e date of the first intravitreal drug
dispensed during the study period was considered as the
index date. Incident drug users were identified as patients
having at least one-year intravitreal anti-VEGF or dexa-
methasone-free period prior to the index date.
2.3. Study Population. )e inclusion criteria were as follows:
patients with at least one year of continuous database history
in the claims databases having at least one pharmacy claim
for the study drugs during the observation years. Patients
were followed until death, disenrollment from the local
healthcare system, or end of the study, whichever occurred
first.
2.4. Data Analysis. Descriptive statistics were reported as
medians, along with interquartile range (IQR), or absolute
frequency and percentages, for continuous and categorical
variables, respectively. )e crude yearly prevalence of use,
along with 95% confidence intervals (CIs), of an intravitreal
anti-VEGF drug as a class and by individual drug and
dexamethasone was calculated for each region and calendar
year. )e yearly frequency of individual drug use over the
study period was also estimated as percentage of ranibizu-
mab, aflibercept, pegaptanib, or dexamethasone users on the
total number of any intravitreal drug users.
Incident users of study drugs were described in terms of
demographics and clinical characteristics such as comor-
bidities (identified any time prior to the index date),
Charlson Comorbidity Index (CCI) [11], concomitant drug
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use, and number of drugs dispensed (identified within 90
days prior to the index date). For incident users having at
least one year of follow-up after cohort entry, the time gap in
days between two consecutive pharmacy claims was cal-
culated and was depicted graphically by means of box plots.
Since Lombardy regional claims database also contains the
date of the intravitreal injection administration, recorded as
a procedure code, sensitivity analyses were conducted in this
catchment area to ascertain to what degree the drug dis-
pensing date coincided with the drug administration date.
Furthermore, a switching pattern was investigated among
incident study drug users in the first year of treatment.
Switching was defined as the first presence of a pharmacy
claim for a study drug other than the index drug occurring
within more than 25 days of the index date.
Patients with pharmacy claims less than 25 days apart
were considered to be bilaterally treated, based on anti-
VEGF SPC recommendations [5, 6]. )e dexamethasone
SPC does not specifically recommend a minimum period to
receive implants in both eyes, apart from not recommending
same-day treatment in both eyes. However, based on clinical
experience, re-treatment with dexamethasone within less
than 25 days is likely to indicate bilateral treatment.
Among incident users of aflibercept and ranibizumab
who did not switch drugs in the first year of therapy, the
number of patients who were given only 3 pharmacy claims
during one year of follow-up, i.e., the minimum induction
phase as recommended by the SPC, was identified. )e
underlying rationale is that discontinuing treatment before a
subsequent treat-and-extend or PRN phase of treatment is
potentially inappropriate. Pegaptanib and dexamethasone
users were excluded from this analysis since the SPC does
not recommend an induction phase. Finally, among incident
users of any intravitreal drug with one year of follow-up, the
number of patients who were given only one pharmacy
claim was calculated.
Since bilateral treatment or indication of drug use was
not recorded in claims data, proxy algorithms are required to
identify such clinical features: claims data from Sicily were
linked with prospective clinical data where the information
about these clinical features was available (i.e., the gold
standard). )e following three algorithms were applied: (1)
bilateral treatment: in line with the SPC, anti-VEGF users
were considered to be bilaterally treated if the interval be-
tween two claims for anti-VEGF drugs was less than 25 days;
(2) DME (narrow definition): DME was identified based on
(a) a diabetes diagnosis in a hospital discharge record or (b)
at least two pharmacy claims for antidiabetic drugs and a
diagnosis of DME in a hospital discharge record; (3) DME
(broad definition): DME was defined based on (a) a diabetes
diagnosis in a hospital discharge record or (b) at least two
pharmacy claims for antidiabetic drugs. )e diagnostic and
predictive accuracy of each claims-based algorithm was
evaluated by calculating the sensitivity, specificity, overall
accuracy, positive predictive value (PPV), and negative
predictive value (NPV) with respective 95% CIs [12].
All statistical analyses were performed using SAS Release
9.4 (SAS Institute, Cary, NC, USA) and SPSS/PC, Version 15
(SPSS Inc., Chicago, Illinois, USA). Plots were produced
using SAS and Cytoscape software (http://www.cytoscape.
org/).
3. Results
3.1. Prevalence, Incidence of Use, and Characterization of
Incident Users of Study Drugs. )e catchment areas covered
approximately 18 million persons, i.e., almost a third of the
Italian population. From 2010 to 2016, at least one study
drug was dispensed to 4.8 per 10,000 persons (Figure 1).
Stratifying by region, the prevalence of anti-VEGF drug
users in the general population was much higher in Lom-
bardy than other regions, ranging from 2.65 (95% CI:
2.55–2.75) anti-VEGF users per 10,000 persons in 2010 to
5.74 (95% CI: 5.60–5.89) anti-VEGF users per 10,000 per-
sons in 2016. In the other regions, the prevalence was lower,
particularly in Basilicata (Figure 2).
Between 2012 and 2013, the anti-VEGF drug use more
than doubled in Lombardy and Sicily, the only two regions
where data for these years was available (0.02 vs. 1.08 anti-
VEGF users per 10,000 persons in Sicily and 2.49 vs. 6.27
anti-VEGF users per 10,000 persons in Lombardy). )e
yearly prevalence of dexamethasone use showed an in-
creasing trend which was most clearly seen in Lombardy,
starting at 0.15 (95% CI: 0.12–0.17) dexamethasone users per
10,000 persons to 1.37 (95% CI: 1.30–1.45) per 10,000
persons in 2016.
Among the prevalent users of any intravitreal drug, the
yearly distribution of drug use changed over time: ranibi-
zumab gradually decreased from 90% in 2010 to 53% in 2016,
while aflibercept use increased from approximately 7% in
2014 to 30% in 2016. Pegaptanib gradually fell into disuse.
Dexamethasone use increased from 10% in 2013 to 18% in
2016 (Supplementary Material 3).
Among the users of anti-VEGF drugs, 40,815 (97.5% of
patients with at least one pharmacy claim for a study drug)
were incident users. )e most frequently dispensed drug at
cohort entry was ranibizumab (N� 30,298; 74.0% of new
intravitreal drug users) while the least common was
pegaptanib (N� 525; 1.28% of new intravitreal drug users)
(Table 1).
Overall, 53.5% (N� 25,317) of the incident ranibizumab
users and 82.4% (N� 3,864) of the incident aflibercept users
with at least 2 pharmacy claims had a median treatment gap
of 1 month (IQR: 34–56), in line with the SPC. )is dis-
tribution remained similar among ranibizumab and afli-
bercept users between their second and third doses of anti-
VEGF (Figure 3).
)e IQR of these initial treatment gaps was relatively
narrow, suggesting low variability. From the fourth phar-
macy claim onwards, the median treatment gap was much
higher, with a markedly wider IQR (ranibizumab: 105 (IQR:
60–190) days, aflibercept: 72 (IQR: 63–125) days). )e
median and IQR values of the treatment gap remained
constant from the fifth pharmacy claim onward. )e sen-
sitivity analysis using the drug administration date in place
of drug dispensing date in the Lombardy claims database
(Supplementary Material 4) confirmed the main results
(Supplementary Materials 5 and 6).
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Dexamethasone users were found to generally have a
pharmacy claim every 180 days (Figure 4).
)e median time between the first and the second
dexamethasone pharmacy claimwas 183 days (IQR: 145–245
days); this IQR suggests that some users are retreated just
before or little later (up to approximately 40 days earlier or
60 days later) than expected based on SPC.)e same median
treatment gap and interquartile range were observed until
the fifth pharmacy claim.
)erapeutic switching occurred in 8.0% (N� 2,701) of
incident users with at least two pharmacy claims during the
first year of treatment (N� 33,637) (Figure 5). Switching was
most frequently observed from dexamethasone to ranibi-
zumab (16.8%).
In the first year of treatment, N� 6,601 (16.0% of all
incident users) were likely treated in both eyes, since they
had consecutive pharmacy claims within 25 days of each
other. Users of dexamethasone were most commonly bi-
laterally treated based on our algorithm (33.3% of all inci-
dent dexamethasone users), followed by ranibizumab users
(14.6% of all incident ranibizumab users).
Among incident users of intravitreal anti-VEGF drugs or
dexamethasone with ≥1 year of follow-up (N� 30,745),
16.0% (N� 4,890) had only one pharmacy claim. Stratifying
by a single drug, ranibizumab users were most commonly
dispensed one drug only (N� 2,970; 60.9% of patients with
one pharmacy claim). Among the incident users of rani-
bizumab who did not switch in the first year of treatment
(N� 23,037), 7,896 (34.2%) were given only the minimum
loading dose of 3 injections. Among 1,978 incident users of
aflibercept who did not switch in the first year of treatment,
550 (27.8%) received the minimum loading dose of 3
injections.
)e identification of bilaterally treated patients or those
affected with DME could be carried out in 380 Sicilian
patients identified in the claims data for whom prospectively
collected clinical data was available and could be linked to
the claims data. For the detection of bilateral treatment, the
algorithm achieved an overall accuracy of 83.8% (95% CI:
79.7–87.3). Concerning the detection of DME, the algorithm
having a narrow definition achieved a high overall accuracy
of 72.3% (95% CI: 67.5–76.8) (Supplementary Material 7).
Both these results suggest a good overall identification of
patients.
4. Discussion
To date, this is the only drug utilization study exploring the
real-world pattern of intravitreal anti-VEGF drug and
dexamethasone use in Italy, using data from four large
Italian regions covering approximately 30% of the Italian
population. )e main finding from this study was the in-
creasing use of intravitreal drugs in Italy. )e prevalence of
anti-VEGF drug use was generally higher than the use of
dexamethasone, with this being most evident in Lombardy,
where after doubling abruptly in 2013, it remained constant
until 2016. A similar increase in intravitreal anti-VEGF drug
use was seen at the national level in the Italian National
Report on Medicines Use (OsMed), where the transition
between 2012 and 2013 was marked by an abrupt and large
increase in anti-VEGF use of over 116% [13, 14]. We hy-
pothesize that this sudden increase is related to a regulatory
event in 2012 when the Italian Drug Agency removed the
anti-VEGF drug bevacizumab from the list of nationally
reimbursed drugs used in off-label ways for ophthalmo-
logical indications after the European Medicines Agency
expressed concerns about its safety [15]. Indeed, over the
study period, we were able to quantify the use of exclusively
off-label bevacizumab users ranging from only 1% in Sicily
to 7% in Lombardy.
)e high prevalence of anti-VEGF use in Lombardy is in
line with the 2017 regional Italian National Report on
Medicines Use, where intravitreal anti-VEGF drug use was
26% higher than the national average, while, in Sicily and
Calabria, anti-VEGF drug use was 11% and 29% lower than
Inhabitants during 2010–2016 in Lombardy, Sicily, Calabria, and
Basilicata∗:
Lombardy N = 9,916,664 (56.6%)
Sicily N = 5,063,570 (28.9%)
Calabria N = 1,975,895 (11.3%)
Basilicata N = 574,767 (3.3%)
Prevalent intravitreal anti-VEGF drug or dexamethasone users:
N = 41,836
Lombardy N = 36,310 (86.8%)
Sicily N = 4,326 (10.3%)
Calabria N = 910 (2.2%)
Basilicata N = 290 (0.7%)
Incident intravitreal anti-VEGF drug or dexamethasone users:
N = 40,815 (97.5%)
Lombardy N = 35,344 (86.6%)
Sicily N = 4,302 (10.5%)
Calabria N = 884 (2.2%)
Basilicata N = 285 (0.7%)
Incident intravitreal anti-VEGF drug or dexamethasone users with 
at least 1 year of FU:
N = 30,745 (75.3%)
Lombardy N = 27,047 (87.9%)
Sicily N = 2,889 (9.3%)
Calabria N = 573 (1.8%)
Basilicata N = 209 (0.6%)
Figure 1: Identification of incident users of intravitreal anti-VEGF
drugs or dexamethasone. Footnote: anti-VEGF: vascular endo-
thelial growth factor; ID: Index Date (i.e., date of the first anti-
VEGF or intravitreal dexamethasone dispensing during the study
years). ∗Data availability ranged from 2010 to 2016 in Lombardy,
from 2012 to 2015 in Calabria, and from 2012 to 2016 in Sicily and
Basilicata. )e crude numbers of inhabitants of each region used to
calculate the mean yearly populations were based on official de-
mographic data published by the Italian National Institute of
Statistics
4 BioMed Research International
the national average, respectively [16–18]. A possible ex-
planation for the higher use of intravitreal drugs in Lom-
bardy concerns the extent of claims data captured, which is
greater in Lombardy. )e higher number of regional claims
captured in Lombardy may be due to the slightly different,
simpler reimbursement processes, as a result of which, more
claims are captured. In addition, it is possible that the higher
prevalence of study drugs in Lombardy may also be due to a
greater number of specialized ophthalmology centres
compared to other regions. To quantify the potential extent
of the underestimation of pharmacy claims, we compared
the number of Sicilian pharmacy claims in 2016 for rani-
bizumab and aflibercept to prescriptions recorded in two
Sicilian drug monitoring registers for these drugs, where
clinicians are obliged by law to record all such prescriptions.
)is comparison was only made in Sicily as data from these
monitoring registries was only available in this region.
Pharmacy claims for ranibizumab and aflibercept were
found to account only for 58% of the pharmacy claims
recorded in the Sicilian registries. )is underreporting in
claims may occur because it is not mandatory to file a drug
claim in order for drugs to be reimbursed.
)e main finding regarding the intravitreal drug use
patterns was the varied treatment regimen in terms of the
interval between one pharmacy claim and another. )e wide
IQRs suggest heterogeneity in the timing of drug
administration. For example, ranibizumab injections com-
monly occurred approximately monthly up to the third
pharmacy claim, potentially indicating loading doses. From
the fourth pharmacy claim onward, ranibizumab was likely
used in a PRN or treat-and-extend approach. )is would be
largely in line with the SPC. )e wide treatment intervals
may reflect personalized treatment, incorrect use, or delays
unrelated to clinical treatment, such as becoming bedridden
or otherwise very disabled, as well as logistical difficulty in
going to the treatment centre [19].
)erapeutic switching occurred in a relatively low
proportion of incident users. )e highest proportion of
switching was observed from dexamethasone to ranibizu-
mab (17%). )e claims do not provide detail on the reasons
for switching, but in clinical practice, this generally occurs
due to therapeutic inefficacy.
A relatively low proportion of incident intravitreal drug
users was found to be bilaterally treated, at 16.0%
(N� 6,601). At the moment of writing, there are no similar
studies to which the present study can be compared. Both
ranibizumab and dexamethasone were the most common
drugs utilized in patients whose drug dispensing patterns
suggested bilateral treatment. )is is supported by the high
prevalence of DME among neovascular diseases, where







































Figure 2: Yearly prevalence of use per 10,000 persons of intravitreal anti-VEGF or dexamethasone in the general population, grouped by
region and calendar years (2010–2016). Error bars represent the Wilson score 95% confidence interval (with continuity correction) around
prevalence estimates.
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Among incident users with ≥1 year of observation time,
16.0% of users received only 1 pharmacy claim.)is was seen
particularly for ranibizumab and dexamethasone users. )e
reasons may be similar to those for excessively short or
long treatment intervals: adverse drug reactions, nonresponse
(e.g., in advanced state of disease), or other situations related
to older age (e.g., death or problems related to the poor or
difficult mobility of these subjects) which could prompt
suspension of treatment or a diagnosis which requires
nonpharmacologic treatment.












Female 16,735 (55.2) 2,594 (55.3) 272 (51.8) 2,442 (46.0) 22,043 (54.0)
Male 13,563 (44.8) 2,095 (44.7) 253 (48.2) 2,861 (54.0) 18,772 (46.0)
Age (years), median (IQR) 73.7 (67.0–82.0) 76.1 (71.0–83.0) 78.0 (73.0–83.0) 70.0 (63.0–78.0) 73.5 (67.0–82.0)
Age classes
<65 5,434 (17.9) 518 (11.0) 30 (5.7) 1,462 (27.6) 7,444 (18.2)
65–74 8,510 (28.1) 1,201 (25.6) 122 (23.2) 1,745 (32.9) 11,578 (28.4)
75–84 11,842 (39.1) 2,116 (45.1) 267 (50.9) 1,699 (32.0) 15,924 (39.0)
≥85 4,512 (14.9) 854 (18.2) 106 (20.2) 397 (7.5) 5,869 (14.4)
Centre
Lombardy 26,270 (86.7) 3,790 (80.8) 508 (96.8) 4,776 (90.1) 35,344 (86.6)
Sicily 3,100 (10.2) 811 (17.3) 10 (1.9) 381 (7.2) 4,302 (10.5)
Calabria 673 (2.2) 80 (1.7) 7 (1.3) 124 (2.3) 884 (2.2)
Basilicata 255 (0.8) 8 (0.2) — 22 (0.4) 285 (0.7)
FU (years), median




Hypertension 23,041 (76.0) 3,717 (79.2) 438 (83.4) 4,046 (76.3) 31,242 (76.5)
Heart failure 1,678 (5.5) 299 (6.4) 33 (6.3) 344 (6.5) 2,354 (5.8)
Arrhythmias 3,268 (10.8) 619 (13.2) 83 (15.8) 545 (10.3) 4,515 (11.1)
Venous or arterial TE 292 (1.0) 44 (0.9) 4 (0.8) 51 (1.0) 391 (1.0)
Ischemic heart disease 2,627 (8.7) 439 (9.4) 66 (12.6) 535 (10.1) 3,667 (9.0)
Stroke and TIA 4,208 (13.8) 744 (15.8) 124 (23.6) 873 (16.4) 6,029 (14.7)
Metabolic disease
Dyslipidemia 13,410 (44.3) 2,133 (45.5) 236 (45.0) 2,352 (44.4) 18,131 (44.4)
Diabetes mellitus 9,918 (32.7) 1,160 (24.7) 101 (19.2) 1,688 (31.8) 12,867 (31.5)
Neurodegenerative
disorders
Parkinson’s disease 686 (2.3) 148 (3.2) 15 (2.9) 122 (2.3) 971 (2.4)
Dementia 207 (0.7) 35 (0.7) 4 (0.8) 24 (0.5) 270 (0.7)
Other diseases
CKD 768 (2.5) 133 (2.8) 16 (3.0) 207 (3.9) 1124 (2.8)
COPD 576 (1.9) 194 (4.1) 5 (1.0) 102 (1.9) 877 (2.1)
Glaucoma 1,767 (5.8) 205 (4.4) 30 (5.7) 283 (5.3) 2,285 (5.6)
Cancer 5,581 (18.4) 1,038 (22.1) 86 (16.4) 900 (17) 7,605 (18.6)
Comorbidities Charlson’s
index
0 16,271 (53.7) 2,628 (56.0) 304 (57.9) 2,894 (54.6) 22,097 (54.1)
1 1,739 (5.7) 370 (7.9) 67 (12.8) 269 (5.1) 2,445 (6.0)
2 1,823 (6.0) 397 (8.5) 37 (7.0) 366 (6.9) 2,623 (6.4)
3 6,027 (19.9) 767 (16.4) 71 (13.5) 950 (17.9) 7,815 (19.1)
≥4 4,438 (14.6) 527 (11.2) 46 (8.8) 824 (15.5) 5,835 (14.3)
Number of drugs∗
0 3,401 (11.2) 559 (11.9) 31 (5.9) 561 (10.6) 4,552 (11.2)
1–3 10,660 (35.2) 1,609 (34.3) 140 (26.7) 1,932 (36.4) 14,341 (35.1)
4–6 9,085 (30.0) 1,435 (30.6) 195 (37.1) 1,555 (29.3) 12,270 (30.1)
>6 7,152 (23.6) 1,086 (23.2) 159 (30.3) 1,255 (23.7) 9,652 (23.6)
CDK: chronic kidney disease; COPD: Chronic obstructive pulmonary disease; FU: follow-up; IQR: interquartile range (i.e., 1st - 3rd quartiles); TE:
thromboembolism; TIA: transient ischemic attack; VEGF: vascular endothelial growth factor. ∗Within 90 days prior to the index date.























Number of incident users
1999 853 380 194 85 38 16 8 3
2 3 4 5 6 7 8 9 10











Figure 4: Distribution of the number of days between intravitreal dexamethasone pharmacy claims among incident users. )e solid line


















Number of incident users
Aflibercept 3864 3311 1977 1487 922 585 344 196 112
Pegaptanib 421 253 142 89 66 44 29 22 10
Ranibizumab 25317 21813 13424 10549 8418 5912 4673 3719 2732
2 3 4 5 6 7 8 9 10















Figure 3: Distribution of the number of days between intravitreal anti-VEGF pharmacy claims among incident users, by drug dispensed at
cohort entry. )e solid line inside each box represents the median value whereas each circled dot represents the mean value.
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)e present study must be interpreted in light of its lim-
itations: results cannot be generalized to the whole Italian
population due to large regional differences [21]. In addition,
drug utilization may be underreported in some regions, al-
though broadly in line with the National Report onMedication
Use. Furthermore, we were not able to evaluate the economic
impact of the use of these drugs as we did not have this in-
formation. Finally, while we were able to validate two im-
portant aspects of ophthalmological treatment, i.e., bilateral
treatment and DME diagnosis, claims data generally lack
clinical detail, which, as a result, could not be reported.
5. Conclusions
Intravitreal drug use increased over time in four large Italian
regions with a notable heterogeneity across regions. Treatment
regimens are not always in line with the respective SPCs,
particularly concerning dexamethasone. )e use of algorithms
for the identification of DME and bilateral patients shows that
claims databases are a valuable source of real-world data for
postmarketing assessment of anti-VEGF drugs.
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